Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva (NYSE:TEVA) launched a public education campaign called “The Other TD” on November 3, 2025 to raise awareness of tardive dyskinesia (TD) and encourage conversations with healthcare providers.
The campaign, supported by Pro Football Hall of Famer Terrell Davis, highlights that TD affects about 25% of people taking certain mental health medications and that an estimated 785,000 Americans may have TD while only ~15% receive a formal diagnosis and ~5% receive treatment. Materials cover symptom recognition, functional and social impact, treatment options that do not interrupt mental health care, and resources for care partners. Visit TheOtherTD.com for more information.
Teva (NYSE: TEVA) said Richard Francis, Teva's President and CEO, will present at two investor conferences in November 2025: UBS Global Healthcare Conference on Monday, November 10, 2025 at 8:45 AM ET and Jefferies London Healthcare Conference on Tuesday, November 18, 2025 at 11:00 AM GMT (6:00 AM ET).
Live webcasts will be available on Teva’s Investor Relations website and archived within 24 hours after each presentation.
Teva (NYSE: TEVA) entered a license and supply agreement with Prestige Biopharma to commercialize Tuznue® (trastuzumab), a biosimilar to Herceptin®, across a majority of European markets.
Tuznue® is approved for breast cancer and metastatic gastric cancer and received European Commission marketing authorization in September 2024. Under the deal, Prestige will produce and supply Tuznue® from its EU‑GMP, single‑use facilities while Teva will market and distribute using its European biosimilars commercial network.
Teva (NYSE: TEVA) announced FDA approval (Oct 10, 2025) of UZEDY® (risperidone) extended‑release injectable suspension for subcutaneous once‑monthly use as monotherapy or adjunctive therapy with lithium or valproate for maintenance treatment of bipolar I disorder (adults).
Approval uses Model‑Informed Drug Development (MIDD) plus prior risperidone data; three monthly dose options are approved: 50 mg, 75 mg, 100 mg. UZEDY reaches therapeutic blood concentrations within 6–24 hours and previously received U.S. approval for adult schizophrenia in 2023. The formulation uses Medincell’s SteadyTeq copolymer for controlled release.
Teva Pharmaceutical Industries (NYSE:TEVA) has released its Q3 2025 Aide Memoire document, which is now accessible on the company's investor relations website. This document serves as a financial modeling aid for investors and analysts, incorporating historical performance data, management's business outlook commentary, and selected third-party information.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has scheduled its third quarter 2025 financial results announcement for November 5, 2025. The company will release its financial results at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET.
Participants must register in advance to receive local or toll-free phone numbers and personal pins. The webcast will be accessible through Teva's investor relations website, with a replay available within 24 hours after the call.
Teva Pharmaceuticals (NYSE: TEVA) presented positive real-world survey data for AUSTEDO XR® (deutetrabenazine) at the 2025 Psych Congress Annual Meeting. The survey of 209 tardive dyskinesia (TD) patients showed remarkable treatment satisfaction, with over 94% reporting movement improvement and more than 89% expressing high satisfaction with the treatment.
Key findings revealed that 77% of patients reported improved social comfort and emotional well-being, while 96% found the medication easy to take. The study included both patients with prior valbenazine use and those without prior treatment, with 96% of participants expressing interest in continuing AUSTEDO XR treatment.
Teva Pharmaceuticals (NYSE:TEVA) announced promising long-term safety data from its Phase 3 SOLARIS trial for olanzapine LAI (TEV-'749), a potential first-in-class long-acting injectable olanzapine treatment for schizophrenia. The trial demonstrated no post-injection delirium/sedation syndrome (PDSS) events through Week 56, with 3,470 total injections administered.
Key findings include a consistent safety profile with other olanzapine formulations, with 74% of participants reporting treatment-emergent adverse events. Common side effects included weight increase (36%) and injection site reactions. The study showed stable symptom improvement and maintained clinical effectiveness, with participants experiencing a mean weight increase of 5.6kg over 48 weeks.
Additionally, new data on UZEDY®, Teva's approved extended-release injectable risperidone, showed a 2.89-day shorter hospital stay compared to Invega Sustenna®, potentially saving $3,200 per hospitalization. Teva plans to submit an NDA for olanzapine LAI in H2 2025.
Teva Pharmaceutical (NYSE:TEVA) has announced plans to present data from its completed Phase 3 SOLARIS trial for Olanzapine LAI (TEV-'749) at the 2025 Psych Congress Annual Meeting in San Diego from September 17-21, 2025.
The company will host an analyst and investor conference call on September 22, 2025, at 11:00 a.m. ET to discuss the trial results. Participants must register in advance to obtain call-in details, and a live webcast will be available on Teva's Investor Relations website, with an archived version accessible within 24 hours after the discussion.
Teva Pharmaceuticals (NYSE: TEVA) announced that the FDA has granted Fast Track designation for emrusolmin (TEV-56286), their investigational treatment for Multiple System Atrophy (MSA). The drug, currently in Phase 2 development, targets the alpha synuclein protein involved in MSA pathogenesis.
Emrusolmin, developed in collaboration with MODAG GmbH, previously received Orphan Drug designation in 2022. The Fast Track status aims to expedite the development and review process for this potential treatment of MSA, a rare and progressive neurodegenerative disorder with no current cure or disease-modifying treatments.